Biological and Environmental Research Ontology

Last uploaded: December 23, 2022
Id http://purl.obolibrary.org/obo/NCIT_C61948
http://purl.obolibrary.org/obo/NCIT_C61948
Preferred Name

Sorafenib
Definitions
A synthetic compound targeting growth signaling and angiogenesis. Sorafenib blocks the enzyme RAF kinase, a critical component of the RAF/MEK/ERK signaling pathway that controls cell division and proliferation; in addition, sorafenib inhibits the VEGFR-2/PDGFR-beta signaling cascade, thereby blocking tumor angiogenesis.
Type http://www.w3.org/2002/07/owl#Class

All Properties

definition

A synthetic compound targeting growth signaling and angiogenesis. Sorafenib blocks the enzyme RAF kinase, a critical component of the RAF/MEK/ERK signaling pathway that controls cell division and proliferation; in addition, sorafenib inhibits the VEGFR-2/PDGFR-beta signaling cascade, thereby blocking tumor angiogenesis.
label
Sorafenib
prefLabel
Sorafenib
Legacy Concept Name
Sorafenib
in_subset
Preferred_Name
Sorafenib
Is_Value_For_GDC_Property
Chemical_Formula
C21H16ClF3N4O3
Display_Name
Sorafenib
Maps_To
Sorafenib
Has_Target
UMLS_CUI
C1516119
FDA_UNII_Code
9ZOQ3TZI87
prefixIRI
NCIT:C61948
Contributing_Source
CTRP
FDA
PCDC
subClassOf
CHEBI_ID
CHEBI:50924
Is_PCDC_AML_Permissible_Value_For_Variable
Has_Salt_Form
code
C61948
type
ALT_DEFINITION
A drug used to treat advanced kidney cancer and a type of liver cancer that cannot be removed by surgery. It is also being studied in the treatment of other types of cancer. Sorafenib stops cells from dividing and may prevent the growth of new blood vessels that tumors need to grow. It is a type of kinase inhibitor and a type of antiangiogenesis agent.
Semantic_Type
Pharmacologic Substance
CAS_Registry
284461-73-0
Add comment
Add proposal
Delete Subject Author Type Created
No notes to display